Picard Medical / SynCardia to Participate in Voice of the Patient Event During AZ Tech Week

Rhea-AI Summary

Picard Medical (NYSE American: PMI) and SynCardia will participate in a Voice of the Patient event during AZ Tech Week on April 9, 2026 in Tucson.

The program spotlights patient experiences with advanced heart failure care, featuring clinicians, a SynCardia implanting surgeon, and a patient speaker.

News Market Reaction – PMI

+0.96%

7 alerts

+0.96% Session close to close

-5.0% Trough in 3 hr 12 min

$75.19M Market Cap

0.8x Rel. Volume

In the Apr 1 session, PMI gained 0.96%, reflecting a mild positive market reaction. Argus tracked a trough of -5.0% from its starting point during tracking. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement spotlights Picard Medical’s participation in an AZ Tech Week “Voice of the Patient...

Analysis

This announcement spotlights Picard Medical’s participation in an AZ Tech Week “Voice of the Patient” program, emphasizing SynCardia’s real-world impact and patient stories. It extends a recent series of awareness and clinical-milestone communications following the company’s 2025 financial results and multiple SynCardia case reports. Investors may track how such visibility efforts support adoption of the FDA- and Health Canada‑approved total artificial heart and complement ongoing development of next-generation platforms.

Key Figures

SynCardia procedures: over 200 procedures Event date: April 9, 2026 Event time: 1:00 PM to 4:00 PM

3 metrics

SynCardia procedures over 200 procedures Dr. Arabia’s experience with SynCardia Total Artificial Heart

Event date April 9, 2026 Voice of the Patient event during AZ Tech Week

Event time 1:00 PM to 4:00 PM Scheduled duration of Voice of the Patient program

Historical Context

5 past events · Latest: Mar 25 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Mar 25	Full-year earnings	Neutral	+3.0%	Reported 2025 revenue growth, higher net loss, stronger cash and balance sheet.
Mar 20	Conference presentation	Positive	+2.7%	Announced ACC.26 poster and exhibit for Emperor Total Artificial Heart platform.
Mar 19	Clinical milestone	Positive	-3.5%	UCSF case with 119 days of SynCardia support before successful transplant.
Mar 17	Clinical milestone	Positive	-10.2%	Four-year (1,636-day) bridge to transplant case using SynCardia Total Artificial Heart.
Mar 13	Media exposure	Positive	-4.7%	BTV on FOX Business feature on SynCardia Total Artificial Heart and next-gen program.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent history shows modest gains on earnings and scientific meeting news, but notable sell-offs following positive clinical case highlights and media exposure, suggesting a tendency for weakness after upbeat operational or clinical announcements.

Recent Company History

Over recent weeks, Picard Medical has issued several updates centered on its SynCardia Total Artificial Heart. On Mar 13–20, the company highlighted TV coverage, multi‑year bridge‑to‑transplant cases, and UCSF clinical milestones, yet shares fell after several of these announcements. By Mar 20, news of presenting preclinical data for the next‑generation Emperor device and on Mar 25 full‑year 2025 results, including $4.94M revenue and a larger net loss, drew modestly positive price reactions. Today’s AZ Tech Week participation fits the pattern of awareness-building news rather than a major financial or regulatory catalyst.

Key Terms

total artificial heart, mechanical circulatory support, advanced heart failure, u.s. fda, +1 more

5 terms

total artificial heart medical

"maker of the world’s first total artificial heart approved by both the U.S. FDA"

A total artificial heart is a surgically implanted mechanical device that replaces the heart’s two main pumping chambers and takes over circulation, acting like a continuous pump that keeps blood moving through the body. Investors care because it is a high-cost, high-stakes medical product whose commercial success depends on clinical trial results, regulatory approvals, hospital adoption, reimbursement rules and long-term patient outcomes — factors that drive revenue potential and risk.

mechanical circulatory support medical

"leader in heart transplantation and mechanical circulatory support, will represent"

Mechanical circulatory support are medical devices that help or take over the heart’s job of moving blood around the body, ranging from temporary external pumps to implanted pumps that assist one or both sides of the heart. For investors, these devices matter because their use drives sales, regulatory scrutiny, reimbursement decisions and long‑term healthcare costs; think of them as a backup engine for a failing heart whose adoption and outcomes influence a company’s market opportunity and risk profile.

advanced heart failure medical

"advanced heart failure care, and the real-world impact of life-sustaining therapies"

Advanced heart failure is a severe, chronic condition in which the heart can no longer pump enough blood to meet the body's needs despite standard treatments, causing frequent symptoms, hospital stays, and the need for specialized therapies. For investors, it signals a clear market for high-cost interventions—drugs, medical devices, hospitals and transplant or mechanical support technologies—so clinical results, approvals, and reimbursement decisions can materially affect revenue, costs and company valuations; think of it as a failing engine that requires costly, often long-term repairs or replacement.

u.s. fda regulatory

"total artificial heart approved by both the U.S. FDA and Health Canada"

The U.S. FDA is the federal agency that reviews and approves drugs, vaccines, medical devices and food products for safety and effectiveness before they can be sold in the United States. For investors, FDA actions act like a gatekeeper — approvals can open the door to large sales and higher company value, while rejections, delays or safety warnings can sharply cut a product’s market potential and a company’s revenue outlook.

health canada regulatory

"total artificial heart approved by both the U.S. FDA and Health Canada"

Health Canada is the government department responsible for overseeing the safety and regulation of health-related products and services in Canada, including medications, medical devices, and vaccines. Its approval and guidelines help ensure that these products are safe and effective for public use. For investors, Health Canada's decisions can influence the success of healthcare companies and affect the availability of new medical treatments in the Canadian market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Arizona industry event will highlight patient experience, advanced heart failure care, and the real-world impact of life-sustaining therapies

TUCSON, Ariz., April 01, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (the “Company”), parent company of SynCardia Systems LLC (“SynCardia”), maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, today announced it will participate in the “Voice of the Patient” event during AZ Tech Week, a program focused on elevating patient perspectives in healthcare innovation hosted by the Arizona Bioindustry Association (“AZBio”), the state’s leading organization representing biotechnology and medical device companies. The event will bring together patients, clinicians, and healthcare leaders to discuss the real-world impact of advanced medical technologies.

Dr. Francisco Arabia, an internationally recognized leader in heart transplantation and mechanical circulatory support, will represent the SynCardia Total Artificial Heart perspective. Dr. Arabia has participated in over 200 SynCardia Total Artificial Heart procedures as an implanting surgeon, proctor, or assisting surgeon at leading transplant and advanced heart failure programs, including Banner University Medical Center Phoenix, the Mayo Clinic in Arizona, Cedars Sinai Medical Center in Los Angeles, and the University of Arizona, among others. He will be joined by Amanda Vaji, Manager of the Mechanical Circulatory Support Program at Banner University Medical Center Phoenix, as well as a patient who will share firsthand experience with SynCardia therapy and recovery from advanced heart failure.

The broader program will feature patients, clinicians, and healthcare leaders discussing the impact of innovative therapies across a range of diseases.

The event will take place on Thursday, April 9, 2026, from 1:00 PM to 4:00 PM at the University of Arizona Health Sciences Innovation Forum in Tucson, Arizona. Registration is available at: https://www.azbio.org/events/voice-of-the-patient-az-tech-week/.

“Advanced heart failure treatment is not only about technology. It is about patients, families, recovery, and quality of life,” said Patrick NJ Schnegelsberg, CEO of the Company and of SynCardia. “We are pleased to participate in this event and support a broader conversation that brings patient experience directly into discussions about innovation and care.”

About Arizona Tech Week

Arizona Tech Week is a statewide innovation conference that brings together founders, investors, researchers, and industry leaders through a series of events hosted across Arizona. The life sciences programming is supported by AZBio. As part of this program, the “Voice of the Patient” event highlights patient perspectives across a range of diseases and medical technologies and brings together clinicians, innovators, and patients to discuss the real-world impact of healthcare innovation. The Company / SynCardia, as member of AZBio, are proud to support the “Voice of the Patient “event as part of AZ Tech Week.

About Picard Medical and SynCardia

Picard Medical, Inc. is the parent company of SynCardia Systems, LLC (“SynCardia”), the Tucson, Arizona-based leader with the only commercially available total artificial heart technology for patients with end-stage heart failure. SynCardia develops, manufactures, and commercializes the SynCardia Total Artificial Heart, an implantable system that assumes the full functions of a failing or failed human heart. It is the first artificial heart approved by both the FDA and Health Canada, and it remains the only commercially available artificial heart in the United States and Canada. With more than 2,100 implants performed at hospitals across 27 countries, the SynCardia Total Artificial Heart is the most widely used and extensively studied artificial heart in the world.

For additional information about Picard Medical, please visit www.picardmedical.com or review the Company’s filings with the U.S. Securities and Exchange Commission at www.sec.gov.

Contact:

Investors
Eric Ribner
Managing Director
LifeSci Advisors LLC
eric@lifesciadvisors.com

Picard Medical, Inc./SynCardia Systems, LLC
IR@picardmedical.com

General/Media
Brittany Lanza
blanza@syncardia.com

FAQ

When and where will Picard Medical (PMI) participate in the Voice of the Patient event during AZ Tech Week?

Picard Medical (PMI) will participate on April 9, 2026, 1:00 PM–4:00 PM in Tucson. According to Picard Medical, the event is held at the University of Arizona Health Sciences Innovation Forum and is part of AZ Tech Week programming focused on patient perspectives.

Who will represent SynCardia and Picard Medical (PMI) at the April 9, 2026 Voice of the Patient event?

Dr. Francisco Arabia will represent SynCardia alongside clinical staff and a patient speaker. According to Picard Medical, Amanda Vaji and a patient with SynCardia experience will join Dr. Arabia to discuss real-world therapy outcomes and recovery.

What topics will Picard Medical (PMI) cover at the Voice of the Patient AZ Tech Week session?

The session will focus on patient experience, advanced heart failure care, and life-sustaining therapies. According to Picard Medical, speakers will discuss clinical perspectives, recovery stories, and how technologies like the SynCardia total artificial heart affect quality of life.

How can investors or attendees register for the Picard Medical (PMI) Voice of the Patient event on April 9, 2026?

Registration is available online via AZBio's event page for the April 9 session. According to Picard Medical, interested attendees should register at the AZBio events portal to secure a spot at the University of Arizona Health Sciences Innovation Forum.

Does Picard Medical (PMI) say the Voice of the Patient event will include patient testimony about SynCardia therapy?

Yes, a patient will share firsthand experience with SynCardia therapy and recovery from advanced heart failure. According to Picard Medical, this testimony is intended to center patients and families in discussions about innovation and clinical care.

Will Picard Medical (PMI) discuss clinical experience with the SynCardia total artificial heart at AZ Tech Week?

Picard Medical (PMI) will present clinical experience, represented by an implanting surgeon with extensive SynCardia cases. According to Picard Medical, Dr. Francisco Arabia has participated in over 200 SynCardia procedures across leading transplant centers.